Clinical Trial Update: Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of TP-0903 (AXL inhibitor) in previously treated chronic lymphocytic leukemia was terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• TP-0903 (AXL inhibitor)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Chronic Lymphocytic Leukemia, CLL | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-02-02